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Our laboratory recently characterized a novel autism spectrum disorder (ASD)-associated de novo missense mutation in
the human dopamine transporter (hDAT) gene SLC6A3 (hDAT T356M). This hDAT variant exhibits dysfunctional forward
and reverse transport properties that may contribute to DA dysfunction in ASD. Here, we report that Zn2+ reverses, at
least in part, the functional deficits of ASD-associated hDAT variant T356M. These data suggest that the molecular
mechanism targeted by Zn2+ to restore partial function in hDAT T356M may be a novel therapeutic target to rescue
functional deficits in hDAT variants associated with ASD.
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Introduction
The dopamine (DA) transporter (DAT) tunes DA neuro-
transmission by active re-uptake of DA from the synapse
[1]. Our laboratory has recently characterized the first
de novo mutation in the human dopamine transporter
(hDAT) reported in a patient diagnosed with autism
spectrum disorder (ASD), which results in a Thr to Met
substitution at site 356 (hDAT T356M). We reported
novel and profound functional abnormalities associated
with the hDAT de novo mutation T356M, resulting in
enhancement of non-vesicular, DAT-dependent DA
release, referred to as anomalous DA efflux. Our data
raise the possibility that anomalous DA efflux (or other
disturbances in DA neurotransmission) may represent a
complication relevant for behavioral abnormalities in
ASD. Extracellular zinc (Zn2+) inhibits DA uptake [2].
Three amino acid side chains have been identified in
DAT which coordinate zinc: H193 in extracellular loop 2
(EL2), H375 in the first helical part of extracellular loop* Correspondence: Heiner.matthies@vanderbilt.edu; Kevin.erreger@vanderbilt.
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unless otherwise stated.4 (EL4A), and E396 in the second helix of extracellular loop
4 (EL4B) [2,3]. Structural data from the DAT-homolog
LeuT in the inward- and outward-facing conformation
suggest that the relative orientation of H375 and E396
shifts during the transport cycle [4].
hDAT T356M displays decreased forward and reverse-
transport function compared with wild-type hDAT [5].
The reduced transport capacity of the mutant was not
associated with a reduction in hDAT surface expression.
Amphetamine (AMPH) is a psychostimulant that targets
the hDAT causing reverse transport of DA (DA efflux)
[6]. hDAT T356M exhibits impaired AMPH-induced
DA efflux. Here, we show that the presence of Zn2+
partially rescues both DA uptake and the AMPH-
induced DA efflux impairments of hDAT T356M. Zn2+
diminishes the anomalous DA efflux property of the
hDAT T356M, which might account for its ability to
partially rescue transporter functions. Rescue of hDAT
function by Zn2+ might reveal a new molecular mechanism
to target for pharmacological intervention in patients with
ASD.Results
Zn2+ enhances [3H]DA uptake in hDAT T356M
CHO cells were transiently transfected with either wild-
type hDAT or hDAT T356M. Cells were incubated with 50al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Zn2+ partially reverses the hDAT T356M deficits in [3H]DA uptake and amphetamine (AMPH)-mediated efflux. Methods were as
previously described in Hamilton et al. [5]. (A) [3H]DA uptake counts (cpm) are plotted for hDAT and hDAT T356M over a range of Zn2+ concentrations.
While Zn2+ inhibits hDAT [3H]DA uptake, Zn2+ instead increases hDAT T356M [3H]DA uptake (*p< 0.05 by one-way ANOVA followed by Dunnett’s test
compared to 0 Zn2+ control; n= 4). (B) (Top) Representative AMPH-induced amperometric currents (reflecting DA efflux) are displayed in the presence or
absence of 100 μM Zn2+. Arrows indicate the application of 10 μM AMPH. (Bottom) Maximal DA efflux amperometric current recorded in the presence of
Zn2+ normalized to maximal current recorded in the presence of vehicle. (*p< 0.05 by paired Student’s t-test; n= 5). (C) (Top) Representative Zn2+-induced
change in amperometric currents are displayed in response to 100 μM Zn2+ or vehicle control. Arrows indicate the application of 100 μM Zn2+. (Bottom)
Change in amperometric current recorded in response to 100 μM Zn2+ or vehicle control (*p< 0.05 by paired Student’s t-test; n= 5).
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concentrations of Zn2+. Consistent with previous reports
[2,3], Zn2+ decreases the DA uptake rate for wild-type
hDAT (Figure 1A, filled squares). In contrast, for hDAT
T356M cells, Zn2+ increases DA uptake, partially reversing
the functional deficit of this variant (Figure 1A, open
circles).
Zn2+ enhances AMPH-induced DA efflux in hDAT T356M
To specifically measure reverse transport, DA was loaded
into the cytoplasm of hDAT T356M cells by a whole-cell
patch clamp pipette held in current-clamp mode. This con-
figuration supplies intracellular DA directly to the cell inde-
pendent of forward transport by hDAT and allows the cell
to control its membrane voltage. The whole-cell patch pip-
ette was filled with an internal solution containing 2 mM
DA as described previously [5]. DA efflux in response to
10 μM AMPH was measured by amperometry in the pres-
ence of 100 μM Zn2+ or vehicle control [5]. Representative
amperometric traces are shown in Figure 1B (top). The
peak of DA efflux normalized to vehicle control is shown in
Figure 1B (bottom). Zn2+ increases AMPH-induced DA
efflux in hDAT T356M compared to vehicle control
(Figure 1B), indicating an enhancement of reverse
transport DA in the presence of Zn2+. For comparison,
Zn2+ partially rescues AMPH-induced DA efflux for
hDAT T356M to a level of 48% ± 12% of wild-type
hDAT AMPH-induced DA efflux [5].
Zn2+ decreases baseline anomalous DA efflux in hDAT
T356M
Using the whole-cell patch clamp technique coupled to
amperometry, the effect of 100 μM Zn2+ on the baseline
(anomalous) DA efflux of hDAT T356M was studied. Thewhole-cell patch pipette delivered intracellular DA into
the cell in current-clamp mode. To determine the effect of
Zn2+ on baseline DA efflux, the change in amperometric
current was compared following the application of
100 μM Zn2+ or vehicle control. Baseline DA efflux
decreased significantly in the presence of Zn2+ in compari-
son with that of vehicle, indicating that Zn2+ inhibits the
constitutive DA efflux by hDAT T356M. Representative
amperometric traces are shown in Figure 1C (top), and
mean values are plotted in Figure 1C (bottom).
Discussion
Here, we explore the potential for Zn2+ in rescuing the bio-
physical abnormalities in the hDAT variant T356M, which
we recently reported in Hamilton et al. [5]. These func-
tional deficits in hDAT T356M may contribute to the dys-
function in DA neurotransmission associated with ASD.
Zn2+ was previously shown to partially restore DA uptake
function in DAT mutant Y335A, which exhibits low uptake
under basal conditions [7]. Here, we demonstrate that Zn2+
reverses deficits in both forward and reverse transport in
the T356M variant. Additionally, Zn2+ decreases baseline
anomalous DA efflux of the hDAT T356M de novo muta-
tion, possibly providing an explanation for the positive
effects of Zn2+ on the uptake and efflux properties of this
mutant transporter. This is a novel and intriguing finding
in terms of ameliorating irregularities in DAT function in a
de novo ASD-associated mutation.
T356 is located in transmembrane domain 7, and
the hDAT Zn2+ binding site spans the spatial micro-
environment between the transmembrane helices 7
and 8 and extracellular loop 2 (EL2) [8,9]. Binding of
Zn2+ to DAT alters the conformational equilibrium
between the inward- and outward-facing state of the
Hamilton et al. Molecular Autism  (2015) 6:8 Page 3 of 3DAT [8,9]. However, mutation of an intracellular tyro-
sine to alanine (Y335A) converts the inhibitory Zn2+
switch into an activating Zn2+ switch, whereby Zn2+
rescues functions of the Y335A mutant transporter
[7,8]. Therefore, the functional impact of Zn2+ binding
to mutant transporters can be different than for wild-
type hDAT as we observe here for T356M (Figure 1A).
Whereas Zn2+ has been suggested to promote the out-
ward facing conformation of wild-type hDAT, the
structural effect of Zn2+ binding to hDAT T356M is
unknown and remains an interesting topic for future
investigation.
Clinical data have previously established that mean serum
Zn2+ levels are significantly lower in children diagnosed
with ASD compared to unaffected children and that there
exist disturbances in Zn2+ metabolism in patients diag-
nosed with ASD [10-12]. hDAT T356M is the first de novo
DAT mutation found in a patient with ASD, and hDAT
T356M functional deficits can partially be rescued by Zn2+.
Whether or not Zn2+ regulation of hDAT may be directly
relevant for the etiology of ASD is presently unknown.
However, our work suggests that the molecular mechanism
engaged by Zn2+ to partially restore function in hDAT
T356M may be a novel therapeutic target to rescue, at least
in part, functional deficits in hDAT variants associated with
ASD.
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